-transparent.png){kind=logo}
The effect of the opioid heptapeptide Met5-enkephalin-Arg6-Phe7 was measured on the contractions of the longitudinal muscle of the guinea-pig ileum and mouse vas deferens; on release of endogenous and newly synthesized acetylcholine from the longitudinal muscle strip preparation of the guinea-pig ileum and of 3H-noradrenaline from mouse vas deferens. Met5-enkephelin-Arg6-Phe7 depressed the contractions of the longitudinal muscle strip of guinea-pig ileum elicited by low frequency stimulation (IC50 366.5 +/- 71.5 nM). The Ke value of naltrexone against the heptapeptide was found to be 0.50 +/- 0.08 nM. Bestatin prolonged and strongly potentiated the action of the opioid peptide in this tissue while captopril proved to be only slightly effective. Met5-enkephalin-Arg6-Phe7 also inhibited neuroeffector transmission in the mouse vas deferens with an IC50 value of 9.44 +/- 2.24 nM. The Ke value of naltrexone was 6.33 +/- 1.22 nM against the heptapeptide. Met5-enkephalin-Arg6-Phe7 (10(-5) M) failed to affect the low frequency stimulated release of endogenous acetylcholine from the guinea-pig ileum preparation. Addition of either bestatin or captopril with the heptapeptide resulted in a reduction of acetylcholine output. The opioid peptide by itself decreased the release of newly synthesized acetylcholine outflow from this organ. Met5-enkephalin-Arg6-Phe7 also reduced the 3H-noradrenaline outflow from mouse vas deferens and this effect was antagonized by naltrexone. From our data we conclude that Met5-enkephalin-Arg6-Phe7 affects the neural transmission of peripheral autonomically innervated organs by depressing the release of neurotransmitter. In vitro it has enkephalin-like character with a preference for the so called delta receptor interaction.
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
September 1983,
Neuropharmacology,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
September 1981,
Neuropharmacology,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
January 1987,
European journal of pharmacology,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
May 1983,
Life sciences,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
October 1986,
The Journal of pharmacology and experimental therapeutics,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
March 1994,
European journal of pharmacology,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
August 2006,
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
May 1983,
Life sciences,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
January 1982,
Advances in biochemical psychopharmacology,
L G Hársing, and
A Z Rónai, and
G T Somogyi, and
H Umezawa, and
S Bajusz, and
E S Vizi
April 1983,
Brain research,
